Results 271 to 280 of about 1,068,411 (344)

Clinical characteristics and economic burden of Alzheimer's disease inpatients in Hubei Province, China: a retrospective analysis of hospitalization costs and length of stay. [PDF]

Front Public Health
Chen S, Jia C, Zhang L, Shen Y, Zhou D, Li M, Peng X, Liu W.   +7 more
europepmc   +1 more source

Biotechnological production of 2‐phenylethanol from agroindustrial byproducts: experimental evaluation, techno‐economic analysis, and life cycle assessment

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract 2‐Phenylethanol (2‐PE) is an alcohol with a rosy scent, commonly used as a fragrance, flavoring agent, and preservative in food and cosmetics. This study evaluates 2‐PE bioproduction using apple pomace and whey as low‐cost, biobased substrates for the growth of the yeast strain Kluyveromyces marxianus CBS600.
Fernanda Thimoteo Azevedo Jorge, Nurdana Orynbek, Aiganym Abduraimova, Anastasiya Valakhanovich, Hector Adiel Flores‐Nestor, Marwen Moussa, Claire Saulou‐Bérion, Ana Karen Sánchez‐Castañeda   +7 more
wiley   +1 more source

Exploring pediatric palliative care in Luxembourg: a mixed-methods study. [PDF]

BMC Palliat Care
Massaad M, Downing J, Allard E, Friedel M.   +3 more
europepmc   +1 more source

Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population‐based cohort of pregnancies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess the risk of major congenital malformations following first‐trimester pseudoephedrine (PSE) exposure. Methods A population‐based observational cohort study was conducted on pregnancies of women aged 15–49 years, insured by Clalit Health Services in southern Israel, who gave birth or had elective ...
Saar Dor, Tal Michael, Yael Levi, Gali Pariente, Eitan Lunenfeld, Amalia Levy, Shira Birenstock‐Cohen, Sharon Daniel   +7 more
wiley   +1 more source

Making health insurance responsive to citizens: learning from six low-income and middle-income countries. [PDF]

BMJ Glob Health
Ismail A, Mathauer I, Akweongo P, Bolivar Vargas MC, Desai S, Raharja DP, Ogundimu MA, Stojisavljevic S, De Allegri M, Shroff ZC.   +9 more
europepmc   +1 more source

Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Phenoconversion, a genotype‐phenotype mismatch, challenges a successful implementation of personalized medicine. The aim of this study was to detect and determine phenoconversion using the solanidine metabolites 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) and 4‐OH‐solanidine as diet‐derived cytochrome P450 2D6 (CYP2D6) biomarkers in a ...
Jens Andreas Sarömba, Julian Peter Müller, Jolanta Tupiec, Anjali Roeth, Berkan Kurt, Florian Kahles, Thea Laurentius, Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Facilitators and barriers of healthcare financing modalities for universal maternal healthcare services in East Africa: a qualitative systematic review. [PDF]

BMC Health Serv Res
Debie A, Wilson A, Geremew AB, Roberts CT, Wassie MM, Stephens JH.   +5 more
europepmc   +1 more source

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Aims Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes
Louise Rabbitt, Áine Keogh, Linda Duane, John Ferguson, Anna Hobbins, Brian E. McGuire, Patrick Gillespie, Laurence J. Egan   +7 more
wiley   +1 more source

Self-Medication with NSAIDs in Gondar city: prevalence, predictors, and public health implications. [PDF]

Sci Rep
Ayenew W, Tegegne AA, Genet G, Limenh LW, Yohannes L, Seid AM, Alemayehu TT, Simegn W.   +7 more
europepmc   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source